Lactobacillus reuteri

Limosilactobacillus reuteri

Interstellar grade B+

Human trial evidence: Randomized human trials, or a meta-analysis of them, measuring this pathway's own endpoint — either a clinical outcome or a validated biomarker.

Appears on 2 blend pages, each linked below.

Pooling eight randomized trials in 1,087 people, Lactobacillus reuteri added to eradication therapy raised clearance from 72.6 to 80.0 percent.

What the evidence shows

Every line below is carried on the blend page that makes the claim. Follow it to the pathway and its sources.

Where it appears

2 blend pages carry this ingredient. Open it and you will find this ingredient in the list.

• Glucose Blocker (Postprandial Control)
• Helico (Gastric Colonization Defense)

Pathways it touches